-
Universal CAR-NKT therapy announces the latest clinical data, still effective in CAR-T therapy for relapsed patients
Time of Update: 2022-05-31
Recommended reading: Cell sub-issue: Super-powered natural killer cell CAR-iNKT, a more effective "spot" immunotherapy for cancerYimai Meng broke the news In September 2019, researchers at UCLA made a new progress, they Using genetically engineered human hematopoietic stem cells to generate iNKT cells for cancer therapy effectively inhibits tumor growth in mice with multiple myeloma and melanoma .
-
Nature's universal CAR-T announces preclinical data targeting two hematological malignancies
Time of Update: 2022-05-29
▲ The process of the mouse experiment, picture source: Nature communications At the same time, the published preclinical data also showed that UCART123 effectively eliminated AML without significant impact on normal hematopoietic progenitor cells; it proved that UCART123 has strong anti-BPDCN activity; Human evaluation for the treatment of r/r AML (adult relapsed or refractory acute myeloid leukemia) is also currently in Phase 1 clinical trials of the AMELI-01 study .
-
Universal CAR-NK for relapsed/refractory acute myeloid leukemia (AML), 3/5 cases achieved CR
Time of Update: 2022-05-25
The most intriguing clinical data is that high-dose ( 10x108 or 15x108 CAR -NK cells, 3 infusions) showed a good response in AML, with 3 CRs in 5 subjects, of which 2 had minimal MRD.
-
Universal CAR-NK for relapsed/refractory B-cell lymphoma, 3/6 cases achieved CR
Time of Update: 2022-05-25
On April 25, U. S. time, Nkarta Therapeutic (later known as Nkarta) announced the latest clinical data on the company’s two CAR-NK pipelines, NKX101 (targeting NKG2D) and NKX019 (targeting CD19), in
-
Universal "modular" CAR-T: Innovent continues to develop cell therapy
Time of Update: 2022-05-24
In this collaboration, Innovent can develop 2:1 bispecific T-cell antibodies and general-purpose CAR-T therapy for hematological and solid tumor treatment using Roche's patented technology, and is responsible for product development, manufacturing and commercialization , the specific transaction amount was not disclosed .
-
Innovent Announces First Clinical Patient Dosing of Universal "Modular" CAR-T Cell Drug IBI345
Time of Update: 2022-05-02
The principal investigator of the study, Secretary of the Party Committee of the First Affiliated Hospital of Soochow University, Chief Physician of the Department of Gastroenterology, and Professor Chen Weichang pointed out: "Solid tumors such as gastric cancer and pancreatic cancer are malignant tumors with high incidence in the world, and Claudin18.
-
2022 EBMT Voice of China Universal anti-CD123 CAR-γδ T cells combined with donor lymphocyte
Time of Update: 2022-04-30
The team of Professor Jiang Erlie from the Hospital of Hematology, Chinese Academy of Medical Sciences applied universal anti-CD123 CAR-γδT cells combined with DLI to a patient with AML who had relapsed after allo-HSCT, and evaluated the efficacy and safety .
-
JCO (IF=45) Xu Kailin's team from Xuzhou Medical University found that the combination of B cell
Time of Update: 2022-04-29
The combination of iNature anti-B cell maturation antigen (BCMA) and anti-CD19 chimeric antigen receptor (CAR) T cells induces high response rates in relapsed or refractory (R/R) multiple myeloma (MM) patients, but Long-term outcomes have not been assessed .
-
JACC: Cancer treatment milestone-pay attention to cardiopulmonary adverse events of universal CAR-T therapy!
Time of Update: 2021-11-12
Thrombosis arrhythmiaIn summary, the study found that CAR-T is associated with cardiopulmonary adverse events including tachycardia, cardiomyopathy, pericardial and pleural diseases, and VTEs .
In summary, the study found that CAR-T is associated with cardiopulmonary adverse events including tachycardia, cardiomyopathy, pericardial and pleural diseases, and VTEs .
-
Professor Huang He: New Progress in Research on Universal CAR-T Cells The 16th National Leukemia and Lymphoma Academic Conference
Time of Update: 2021-10-21
The research results reported at the 2018 ASH Conference showed that the CR/Complete Remission (CRi) rate with incomplete recovery of hematology reached 82% for the universal CAR-T treatment of B-cell acute lymphoblastic leukemia (B-ALL).
-
CCSC: China Foreign Exchange, CAR-T's new idea in the treatment of blood diseases——Tongji Hospital
Time of Update: 2021-10-01
Professor Cao Yang mainly introduced a study of his team on continuous infusion of anti-CD19 and anti-CD22 CAR-T therapy for patients with relapsed and refractory high-risk B-cell lymphoma after transplantation .
-
Allogene's universal BCMA CAR-T cells obtained the U.S. FDA fast-track designation medical Maimeng broke the news
Time of Update: 2021-08-22
Recommended reading: ASCO 2021: Allogene announces the latest clinical data of two allogeneic CD19 CAR-T drug treatments Yimai Meng broke the news that BCMA: MM's popular target Multiple myeloma (MM) is a clonal plasma cell abnormality The proliferative malignant disease is also the second most common hematological malignancy after non-Hodgkin’s lymphoma.
-
"Nature" Sub-Journal: Zhejiang University Gu Zhen's team developed a "cell warehouse" to help CAR-T treat solid tumors
Time of Update: 2021-08-12
At the same time, in the postoperative inflammatory environment, platelets modified with PD-L1 antibodies can be activated and release anti-PD-L1 antibodies, blocking the immune checkpoint inhibition pathway, and enhancing the killing ability of CAR-T cells, which can be more effective Effectively inhibit the recurrence of cancer after surgery .
-
"Universal" allogeneic CD30-CAR EBVST cell therapy!
Time of Update: 2021-05-21
com" target="_blank">"Universal" T cell therapy (TT11X)TT11X is an allogeneic, CD30 chimeric antigen receptor, and Epstein-Barr virus-specific T cell therapy (allogeneic CD30-CAR EBVST) , which is being jointly developed by Baylor College of Medicine in the United States and Tesha Biology.
-
The Xia Ningshao team of Xiamen University reveals the mechanism and key sites of CAR-mediated high-efficiency decapsidation of CVB virus
Time of Update: 2021-03-25
. This research can provide a key basis for the research of CVB vaccines and antiviral drugs, enrich the understanding of the interaction mechanism between the virus and the receptor, and provide an important reference and theoretical basis for the development of high-efficiency broad-spectrum antiviral drugs targeting the viral receptor binding domain .